In January 2020, the U.S. Food and Drug Administration (FDA) conducted a routine inspection of Transcoject GmbH for the third time, following inspections in 2015 and 2017. The inspection, which took place over four days as scheduled, confirmed that the facility meets the requirements of 21 CFR Part 820 "QSR".

At Transcoject, we are committed to supporting our customers in their efforts to enhance patient safety and maintain the highest quality standards. This allows you, as our customer, to focus on what matters most: bringing products to market quickly and efficiently.